Targeting Moderate to Severe Psoriasis: Novel Treatments on the Horizon

Patients with psoriasis (PsO) experience disruptions to their daily functioning due to their condition, with higher disease severity associated with reduced quality of life. The approval of novel therapies over the past several years has greatly expanded the armamentarium for difficult to manage PsO and several agents are in the research pipeline for FDA review. Among these options, small molecule agents targeting new pathways are showing promise in enhancing PsO care, including Janus kinase inhibitors and a recently approved tyrosine kinase 2 (TYK2) inhibitor. Tune into this on-demand webcast to learn about new and emerging therapies for moderate to severe psoriasis featuring leading dermatology experts.

Share

Program Content

Activities

  • Targeting Moderate to Severe Psoriasis
    Targeting Moderate to Severe Psoriasis: Novel Treatments on the Horizon
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2022

    Expires: December 15, 2023

  • Targeted Psoriasis Care
    Novel Therapies for Psoriasis Care: Targeting the JAK-STAT Pathway
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2022

    Expires: December 19, 2023

  • Novel Treatments on the Horizon
    Targeting Moderate to Severe Psoriasis: Novel Treatments on the Horizon
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 17, 2023

    Expires: January 16, 2024

Faculty

cover img faculity

Steven Feldman, MD, PhD

Professor of Dermatology, Pathology and Social Sciences & Health Policy
Wake Forest University School of Medicine
Winston-Salem, North Carolina

cover img faculity

Kristine Kucera, PA-C, MPAS, DHS

Physician Assistant
Bare Dermatology
Dallas, Texas
Adjunct Assistant Professor
UNT Health Science Center, PA Program
Ft. Worth, Texas

Provided by

ProCE Banner

Provided by Partners for Advancing Clinical Education (PACE).

Supporters

This activity is supported by an educational grant from

Bristol Myers Squibb